GRM5 and fragile X syndrome: Given the failure of clinical trials of mGluR5 modulators and the observed variability in subcortical radioligand uptake in PET studies with FXS subjects, it may be suggested that the future of mGluR5 PET radioligands lies in the potential to identify individual subjects with lower regional uptake of the radioligand.